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1 These authors contributed equally to this work.Recently, we found that C1qTNF-related protein 5 (CTRP5) is involved in glucose and lipid metabo-
lism. However, the transcriptional regulation of CTRP5 is largely unknown. Here we demonstrate
the mechanism by which the CTRP5 gene is transcriptionally activated in the liver. CTRP5 is acti-
vated by HNF4a via the region 206/167 of the human CTRP5 promoter. Deletion of this region sig-
niﬁcantly decreased HNF4a-induced CTRP5 promoter activity. Gel shift and chromatin
immunoprecipitation analysis showed that HNF4a directly binds to HNF4a-responsive element at
the region 202/177 of the CTRP5 promoter. Taken together, these results show that hepatocyte
nuclear factor-4a is involved in transcriptional regulation of CTRP5 in the liver.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
C1qTNF-related protein 5 (CTRP5) is a 243-amino acid protein
that consists of an N-terminal signal peptide, a collagen repeat,
and a C-terminal globular domain. It was initially identiﬁed as a
gene responsible for late-onset macular degeneration and long
anterior lens zonules [1]. Mutation of CTRP5 leads to insufﬁcient
levels of secreted CTRP5, causing late-onset retinal macular degen-
eration [1,2]. Recently, CTRP5 was found to belong to a highly con-
served family of adiponectin paralogs [3–5]. Our recent study
showed that CTRP5 mediates translocation of glucose transporter
4 (GLUT4) and fatty acid oxidation via the activation of AMP-acti-
vated protein kinase (AMPK) [6]. Serum CTRP5 levels are signiﬁ-
cantly higher in obese/diabetic animals (OLETF rats, ob/ob mice,
and db/db mice) [6]. Although the expression pattern of CTRP5 is
still not completely clear, several studies showed that CTRP5 is
widely expressed in various tissues, including adipose tissues, li-
ver, spleen, lung, eye, and testis [3,4]. However, the basis for tran-
scriptional regulation of CTRP5 expression is largely unknown.
Because our recent study showed that CTRP5 is involved in glucose
and lipid metabolism, we investigated the transcriptional regula-
tion of CTRP5 in the liver, which plays an important role in both
glucose and lipid metabolism. In this study, we present evidencechemical Societies. Published by E
.that hepatocyte nuclear factor-4a (HNF4a) is an essential tran-
scription factor for CTRP5 gene expression in SK-Hep1 cells.
2. Materials and methods
2.1. Reagents
Polyclonal antibodies directed against HNF4a and NFAT4 were
obtained from Santa Cruz Biotechnology. Normal rabbit IgG was
purchased from Chemicon. Protein G-conjugated agarose beads
were obtained from Upstate. All oligonucleotides were synthesized
by Bionics (Seoul, Korea).
2.2. Cell culture and transfection
SK-Hep1 cells were grown in Dulbecco’s modiﬁed Eagle med-
ium (DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and the appropriate antibiotics. The cells were trans-
fected with human CTRP5 promoter and/or transcriptional factor
using Welfect-EX, in accordance with the manufacturer’s instruc-
tions (WelGENE).
2.3. Construction of human CTRP5 reporter plasmids
The transcriptional start site of the human CTRP5 gene was
determined by 50 rapid ampliﬁcation of cDNA ends (RACE) (Invitro-
gen) using cDNA from SK-Hep1 cells, in accordance with thelsevier B.V. All rights reserved.
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man CTRP5 promoter region (pC5-1436/+20) was ampliﬁed by
PCR using SK-Hep1 genomic DNA as the template and cloned into
the Asp718I–XhoI sites of the pGL3/basic vector (Promega). For
generation of 50 deletion mutants of the human CTRP5 promoter,
the forward and backward PCR primers were designed to include
Asp718I and XhoI sites, respectively (Table 1). The PCR products
were cloned into the Asp718I and XhoI sites of the pGL3/basic vec-
tor. Deletion of putative HNF4a binding sites were carried out by
two-step PCR mutagenesis with the primers listed in Table 1. All
plasmid constructs were veriﬁed by DNA sequencing (Bionics).
2.4. Reporter gene assays
SK-Hep1 cells in 12-well plates were cotransfected with pGL3/
basic or pC5-luc vector together with pRL-SV40 for constitutive
expression of Renilla luciferase as an internal control. Luciferase
activity was measured 48 h after transfection using a Dual Lucifer-
ase assay kit, in accordance with the manufacturer’s instructions
(Promega). The ratio of ﬁreﬂy luciferase activity to Renilla lucifer-
ase activity was presented in arbitrary units as the relative lucifer-
ase activities.
2.5. EMSA
Nuclear extracts were prepared from SK-Hep1 cells as previ-
ously described [7]. Biotin-labeled oligonucleotides were synthe-
sized, mixed together at an equimolar ratio, and allowed to
anneal for 1 h at 37 C to form the double-stranded probe. The se-
quences of the oligonucleotides used were: forward HNF4a probe,
50-CTT TCT CCC CCT AAA CTT TGG CCG GC-30 (202/177); reverse
HNF4a probe, 50-GCC GGC CAA AGT TTA GGG GGA GAA AG-30; for-
ward non-speciﬁc probe, 50-GTG GTT GTG GAA ACA TTG AC-30; and
reverse non-speciﬁc probe, 50-GTC AAT GTT TCC ACA ACC AC-30.
EMSAs were performed using a LightShift™ chemiluminescent
EMSA kit (Pierce), in accordance with the manufacturer’s instruc-
tions. Brieﬂy, 20 fmol biotin-labeled oligonucleotide was incubated
with 6 lg of nuclear proteins for 20 min at room temperature in
binding buffer [10 mM Tris (pH 7.4), 50 mM KCl, 1 mM dithiothre-
itol, 5 mM MgCl2, 2.5% glycerol, 0.05 mg/ml poly(dI-dC), and 0.05%
NP40]. For competition experiments, 50-, 100-, and 200-fold excess
unlabeled HNF4a-RE or non-speciﬁc oligonucleotide was preincu-
bated for 20 min prior to addition of HNF4a probe. Reaction mix-
tures were resolved on 6% polyacrylamide gel pre-electrophoresedTable 1
DNA sequences of primers used for cloning of the human CTRP5 promoter and its
mutant forms.
Name Nucleotide sequences
50 pC5 50-AAAAGGTACCATCCTCTTGCTTCCTCAC-30
50 pC5-829 50-AAAAGGTACCGCAACAGGCTGCCAGAG-30
50 pC5-650 50-AAATGGTACCGAAGAGAAGTCCTCAGC-30
50 pC5-491 50-AAAAGGTACCCAGCTTCTCCATCGCCTG-30
50 pC5-436 50-AAAAGGTACCGAGCATCTATTCATGTGGC-30
50 pC5-376 50-AAAAGGTACCCCTCTAGAACTCTCCACC-30
50 pC5-326 50-AAAAGGTACCGGTCTGGTCCTTGGTCTC-30
50 pC5-276 50-AAAAGGTACCAACAGGAGGTGCCCTGTG-30
50 pC5-232 50-AAATGGTACCTGTGCCCAGCTCAAGTC-30
50 pC5-206 50-AATTGGTACCTCCTTTCTCCCCCTAAAC-30
50 pC5-166 50-AAAAGGTACCCACCACGAGTTATTTCC-3v
50 pC5-115 50-AAAAGGTACCGAACAACTGGTTTCCTC-30
30 pC5 50-AAATCTCGAGTCCAGTTGGTGGTGCTC-30
50 D-236/-207 50-AATTGGTACCTCCTTTCTCCCCCTAAAC-30
30 D-236/-207 50-AAAAGGTACCGCAGAACTTCGAGAGACG-30
50 D-206/-167 50-AAAAGGTACCGAACAACTGGTTTCCTC-30
30 D-206/-167 50-AAAAGGTACCCACCACGAGTTATTTCC-30for 30 min in 0.5  Tris borate/EDTA, and electrophoresed at 100 V
before being transferred to positively charged nylon membranes
(Pierce). Transferred DNAmolecules were cross-linked to themem-
brane at 120 mJ/cm2 and detected using horseradish peroxidase
(HRP)-conjugated streptavidin (Pierce).
2.6. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the Upstate Biotechnology
ChIP assay kit, in accordance with the manufacturer’s instructions.
Brieﬂy, SK-Hep1 cells were cross-linked by adding formaldehyde to
a ﬁnal concentration of 1% and incubating at room temperature for
10 min. Then, cells were washed with phosphate-buffered saline
(PBS) and sonicated to yield DNA fragments ranging in size from
200 to 1000 base pairs. Sonicated samples were centrifuged for
10 min at 4 C (12 000 rpm), supernatants recovered, diluted 10-
fold into ChIP dilution buffer, and then precleared by incubating
with 75 ll of salmon sperm DNA/protein G-agarose-50% slurry
for 30 min at 4 C with agitation to reduce the non-speciﬁc interac-
tion of chromatin DNA with the agarose beads. Supernatants were
immunoprecipitated with anti-HNF4a antibody (Santa Cruz Bio-
technology) or isotype-matched control antibody (anti-NFAT4,
Santa Cruz Biotechnology). Immunoprecipitated complexes were
eluted from the protein G-agarose beads using elution buffer (1%
SDS, 0.1 M NaHCO3), and the DNA was separated from protein,
then used as templates for PCR reactions. The genomic primer se-
quences were: CTRP5 forward primer (50-TGT GCC CAG CTC AAG
TC-30 (231/215)) and CTRP5 reverse primer (50-GCT GGG AAA
TAA CTC GTG GTG-30 (166/146)). As negative controls, we used
GAPDH primers, as follows: GAPDH forward primer (50-TGC CAC
CCA GAA GAC TGT G-30) and GAPDH reverse primer (50-ATG TAG
GCC ATG AGG TCC AC-30).
2.7. Statistical analysis
Statistical signiﬁcance was assessed using ANOVA. A P value
of <0.05 was considered to be statistically signiﬁcant.3. Results and discussion
3.1. HNF4a can activate human CTRP5 transcription
The CTRP5 gene is transcribed into two forms, monocistronic
and bicistronic transcripts (Fig. 1A). A previous study reported that
CTRP5 and MFRP form a bicistronic transcript in the eye and brain
[8]. To identify the region containing the CTRP5 promoter in liver
cells, the transcription start site of the CTRP5 gene was determined
by 50 RACE-PCR using mRNA isolated from SK-Hep1 cells. From
RACE-PCR using a reverse primer located 71 bp downstream of
the CTRP5 coding region, the mRNA transcription start site was
found to be located 118 bp upstream of the start codon (Fig. 1B)
and designated as +1 in the numbering of the nucleotide sequence
(Fig. 1C). To identify important regions in transcriptional activation
of the human CTRP5 promoter, we generated a series of 50 deletion
mutants of CTRP5 promoter and tested their basal activities in SK-
Hep1 cells. Deletion from 276 to 167 causes a signiﬁcant de-
crease in CTRP5 promoter activity (Fig. 2A), suggesting that the
276/167 region is important for CTRP5 promoter activity. In this
region, elements that may be required for basal and inducible
CTRP5 expression are indicated in Fig. 1C, including Elk-1, HNF4a,
CREB, p300, and GATA3. When the effects of these transcription
factors were examined in SK-Hep1 cells, we found that HNF4a in-
creases CTRP5 promoter activity by approximately 8-fold (Fig. 2B).
HNF4a increases CTRP5 promoter activity in a dose-dependent
manner, whereas an HNF4amutant form that lacks its transactiva-
Fig. 1. Identiﬁcation of the transcriptional start site of the CTRP5 gene in liver cells. (A) A physical map of the human CTRP5 gene isoforms and the strategy for 50-RACE PCR
ampliﬁcation are shown. The location of the primer used for 50-RACE PCR is indicated by an arrow. (B) 50-RACE PCR product was resolved on a 2% agarose gel with only one
speciﬁc band (left panel). The transcriptional start site was determined by sequencing (right panel). (C) Schematic representation of the CTRP5 promoter region. Numbers
indicate position from the transcriptional start site. Putative transcription factor binding sites, which are underlined in the sequence, were identiﬁed using computer-based
programs TESS and TFSEARCH.
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amounts of this mutant form (Fig. 2C and D).
3.2. Localization of the HNF4-responsive region in the human CTRP5
promoter
To investigate whether HNF4a binding sites exist in the region
276/167, a series of 50 deletion mutants of the CTRP5 promoter
were cotransfected with HNF4a expression vector into SK-Hep1
cells. Deletion from 276 to 167 caused a signiﬁcant decrease
in CTRP5 promoter activity (Fig. 2E), indicating that the HNF4a-
responsive region is in the region 276/167. Using computer-
based sequence analysis, we found that there are two putative
HNF4a binding sites in this region (Fig. 1C). To further identify
which region is a cis-responsive element for HNF4a, we generated
CTRP5 promoter mutants lacking each HNF4a binding site
(Fig. 3A). A deletion mutant lacking the ﬁrst HNF4a-responsive re-
gion (D-236/-207) showed promoter activity comparable with that
of the wild-type promoter, whereas a deletion mutant lacking the
second HNF4a-responsive region (D-206/-167) showed a signiﬁ-cant decrease in CTRP5 promoter activity, indicating that the puta-
tive HNF4a binding site at the region 206/167 plays a pivotal
role in HNF4a-responsive CTRP5 transcription (Fig. 3B).
3.3. HNF4a binds to the HNF4a-responsive element in human CTRP5
promoter in cells
To study whether the HNF4a binding site at the region 206/
167 is a functional binding site for nuclear proteins, EMSA was
performed using nuclear extracts from SK-Hep1 cells. A 206/
167 oligonucleotide encompassing the putative HNF4a binding
site at 202/177 of the CTRP5 promoter forms a DNA–protein
complex with SK-Hep1 nuclear extract (Fig. 4A). This binding activ-
ity was dose-dependently competed by high amounts of unlabelled
HNF4a probe but not by a non-speciﬁc probe (Fig. 4A, lanes 3–5).
To further conﬁrm direct binding of HNF4a to the HNF4a-respon-
sive element at the region 202/177 in vivo, we performed chro-
matin immunoprecipitation (ChIP) assays in SK-Hep1 cells
(Fig. 4B). When chromatin DNA was precipitated using an
anti-HNF4a antibody, the 84 bp fragment encompassing the
Fig. 2. HNF4a-dependent enhancement of CTRP5 promoter activity. (A) The full-length (1346/+20) and a series of 50 deletion mutants of the human CTRP5 promoter
constructs were transfected into SK-Hep1 cells. The relative luciferase activities were plotted against that of the full-length promoter, which is set as 100%. Results are
expressed as the means ± S.D. of at least three independent experiments. T-test: *P < 0.01. (B) The CTRP5 promoter construct was cotransfected with the indicated
transcription factors or control vector pRc-CMV into Sk-Hep1 cells. The relative luciferase activities were plotted against that of the control vector, which is set as 1. Results
are expressed as the means ± S.D. of at least three independent experiments. T-test: *P < 0.01. (C) Schematic representation of wild-type and mutant HNF4a. DBD, DNA
binding domain; LBD, ligand binding domain; TAD, transactivation domain. (D) The CTRP5 promoter construct was cotransfected with the indicated amount of wild-type or
mutant HNF4a expression vector into Sk-Hep1 cells. The relative luciferase activities were plotted against that of the CTRP5 promoter in the absence of HNF4a, which is set as
1. Results are expressed as the means ± S.D. of at least three independent experiments. (E) Identiﬁcation of the HNF4a-responsive region of the human CTRP5 promoter. The
full-length (1346/+20) and a series of 50 deletion mutants of the human CTRP5 promoter constructs were cotransfected with HNF4a expression vector or empty vector into
SK-Hep1 cells. The relative luciferase activities were plotted against that of each promoter in the absence of HNF4a, which is set as 1. Results are expressed as the means ± S.D.
of at least three independent experiments. T-test: *P < 0.01.
Fig. 3. Identiﬁcation of the HNF4a-responsive element in the human CTRP5
promoter. (A) Schematic representation of human CTRP5 promoter (650/+20)
with either putative HNF4a-responsive element deleted. (B) Wild-type (650/+20)
and deletion mutants (D-236/-207 and D-206/-167) of the human CTRP5 promoter
constructs were transfected into SK-Hep1 cells. The relative luciferase activities
were plotted against that of each promoter in the absence of HNF4a, which is set as
1. Results are expressed as the means ± S.D. of at least three independent
experiments. T-test: *P < 0.01.
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(Fig. 4B, lane 1). Ampliﬁcation of an equivalent amount of genomic
DNA precipitated with an isotype-matched control antibody only
slightly ampliﬁed the sequence containing the HNF4a-responsive
element (Fig. 4B, lanes 2). As a negative control, any signal was
not observed in PCR ampliﬁcation for GAPDH (Fig. 4B). Taken to-
gether, these results demonstrate that HNF4a speciﬁcally binds
to the HNF4a-responsive element in the human CTRP5 promoter
in living cells.
HNF4a is one of several nuclear receptor proteins and regulates
liver speciﬁc gene expression [9]. It is also expressed in the pan-
creas, stomach, kidney, and intestine. HNF4a is required for the
expression of many genes involved in lipid and glucose metabo-
lism, including apolipoproteins [10–12], insulin [13], glucokinase
[14], and L-carnitine palmitoyltransferase I (L-CPT I) [15]. Muta-
tions in the HNF4a gene cause maturity-onset diabetes of the
young (MODY-1) [16]. In this study, we provide evidence that
HNF4a transcriptionally regulates expression of CTRP5, which is
involved in glucose and fatty acid metabolism. The CTRP5 gene is
transcriptionally activated by HNF4a but not a mutant HNF4a that
lacks the transactivation domain. HNF4a activates the CTRP5 gene
by directly binding to a cis-acting element corresponding to the
202/177 region of the human CTRP5 promoter.
Although the present study shows that HNF4a directly stimu-
lates transcriptional activation of the CTRP5 gene, HNF4a can reg-
ulate gene expression via the activation of other transcriptional
factors or through cooperation with other coactivators. HNF4a
indirectly regulates insulin gene expression via elevation of HNF1a
Fig. 4. HNF4a binds to an HNF4a binding site at the region between 206 and
167 in the human CTRP5 promoter. (A) EMSAs were performed with biotin-
labeled HNF4a-RE oligonucleotide in SK-Hep1 cells. For competition experiments,
unlabeled oligonucleotides were used at 50-, 100-, or 200-fold molar excess to the
labeled probe. Closed arrowhead indicates the speciﬁc bands. (B) Soluble chromatin
was prepared from SK-Hep1 cells for ChIP assays and immunoprecipitated with
anti-HNF4a antibody (lane 1) or an isotype-matched control antibody (lane 2).
Immunoprecipitates were subjected to PCR with primers speciﬁc to the HNF4a-RE
in the CTRP5 promoter (upper panel). As a negative control, GAPDH primers were
used (lower panel).
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tor for HNF4a to enhance target gene expression, including CREB-
binding protein, p300, SRC-1, and PGC-1 [17–19]. In preliminary
studies, we have shown that co-transfection of CREB enhances
HNF4a-induced CTRP5 expression (unpublished data). The mecha-
nism of cooperation between HNF4a and CREB remains to be
investigated.
Recently, we found that CTRP5 mediates activation of AMP-acti-
vated protein kinase (AMPK) in muscle [6] and liver cells (unpub-
lished data), thereby regulating glucose and lipid metabolism in
these tissues. A previous study showed that activation of AMPK
activity in primary liver cells correlated with reduced expression
of HNF4a target genes [20]. Hong and colleagues demonstrated
that AMPK regulates transcriptional activity of HNF4a via inhibi-
tion of dimer formation and decrease of protein stability [21]. Thus,
it is possible that AMPK activation by high amounts of serum
CTRP5 regulates CTRP5 expression via a negative feedback
mechanism.
In summary, we demonstrated that HNF4a plays a key role in
transcriptional regulation of CTRP5. Considering that CTRP5 is in-
volved in glucose and fatty acid metabolism, our work identifying
HNF4a as a cis-acting element for CTRP5 regulation helps elucidate
the regulatory mechanism of CTRP5 in metabolic diseases such as
diabetes and obesity.Acknowledgments
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